 Q BioMed Inc. OTCQB:QBIO has announced a new publication in the Frontiers of Oncology journal supporting the efficacy and further development of its Uttroside-B Utt-B chemotherapeutic to treat liver cancer. In the initial Scientific Reports study, Q BioMed said researchers showed that in animal models Utt-B was 10 times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the US Food and Drug Administration FDA for liver cancer. 